A pharmaceutical company is preparing to register a new medi…
A pharmaceutical company is preparing to register a new medicine simultaneously in South Africa, the European Union, and the United States. The scientific data (Modules 2–5) are complete and aligned with ICH CTD requirements. However, the regulatory team proposes submitting the same Module 1 dossier to all three authorities: South African Health Products Regulatory Authority, European Medicines Agency, and U.S. Food and Drug Administration. What is the MOST appropriate regulatory strategy?
Read Details